Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on…
Biogen and Alkermes got approval from USFDA for Vumertiy, a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.
ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.
Biogen said Monday it will buy Nightstar Therapeutics, a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
Alkermes and Biogen said the FDA will check their novel oral fumarate in development for diroximel fumarate (BIIB098), for the treatment…
Alkermes has received a $50 million payment from Biogen after it reviewed the preliminary gastrointestinal tolerability data from the ongoing…
ProMIS Neurosciences’s lead product candidate for Alzheimer’s disease, PMN310, showed similar ability to cross the blood brain barrier and penetrate…
A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday.
Board of Directors has appointed its former executive vice preisdent Claus Bo Svendsen, as Chief Executive Officer, as it plans to pursue important objectives related to the the Settlement and License Agreement with Biogen.